Bay­er, J&J eye block­buster sup­ple­men­tal OK for Xarel­to; Set­Point rais­es $30M for bio­elec­tron­ics

⇨ The an­ti-clot ther­a­py Xarel­to from Bay­er and J&J may have a much brighter fu­ture now that re­searchers have post­ed its ef­fect on pre­vent­ing heart at­tacks and strokes among pa­tients suf­fer­ing from ath­er­o­scle­ro­sis. Al­ready ap­proved for use, an­a­lysts say the drug could now see its po­ten­tial mar­ket more than dou­ble overnight with an ap­proval in this in­di­ca­tion, which could eas­i­ly be worth well over a bil­lion dol­lars in ad­di­tion­al sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER